www.amgenmedinfo.com
866-572-6436
DISEASE EDUCATION:
Underlined terms can be clicked for definition.
There are two main types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). SCLC makes up about 15% of lung cancer cases.
Small cell lung cancer (SCLC) is a fast-growing cancer that develops when a specific type of lung cell, called a neuroendocrine cell, grows out of control.
Patients with SCLC are often diagnosed after their cancer has reached an advanced stage because symptoms don't typically appear early in the disease.
To determine if you may be eligible for a clinical study for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.
The stage of the cancer, or how far it has spread, will determine whether you have limited stage or extensive stage disease. The stage of the cancer will also affect your treatment options. Most patients have extensive stage disease at the time of diagnosis.
Limited stage cancer is often treated with surgery, radiation, and/or chemotherapy, while extensive stage SCLC requires chemotherapy and sometimes immunotherapy. Extensive stage SCLC has a high rate of recurrence after the first treatment.
For patients with extensive stage SCLC, clinical studies may be an option.
What is the
DeLLphi-304 study?
DeLLphi-304 is a clinical study comparing tarlatamab with standard of care chemotherapy in patients whose cancer has returned after first-line treatment.
If you are a physician or another healthcare professional interested in learning more about a tarlatamab clinical study or referring a patient, please contact an Amgen Medical Information Healthcare Professional.
Where can I get more information?
To determine if you may be eligible for a clinical study for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.